A61K - Preparations for medical, dental, or toilet purposes

More topics under "A61K - Preparations for medical, dental, or toilet purposes" (2,585,043)
A61K 101 - Radioactive non-metals (526)
A61K 103 - Radioactive metals (481)
A61K 125 - Containing or obtained from roots, bulbs, tubers, corms or rhizomes (2,645)
A61K 127 - Containing or obtained from leaves (1,806)
A61K 129 - Containing or obtained from bark (325)
A61K 131 - Containing or obtained from seeds, nuts, fruits or grains (1,932)
A61K 133 - Containing or obtained from flowers or blossoms (665)
A61K 135 - Containing or obtained from stems, stalks, branches, twigs or shoots (756)
A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
A61K 33 - Medicinal preparations containing inorganic active ingredients (56,213)
A61K 35 - Medicinal preparations containing material or reaction products thereof with undetermined constitution (125,838)
A61K 36 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines (179,316)
A61K 38 - Medicinal preparations containing peptides (316,240)
A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
A61K 41 - Medicinal preparations obtained by treating materials with wave energy or particle radiation (9,445)
A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
A61K 49 - Preparations for testing in vivo (35,376)
A61K 50 - Electrically conductive preparations for use in therapy or testing in vivo, e.g. conductive adhesives or gels to be used with electrodes for electrocardiography (ecg) or for transcutaneous drug administration (62)
A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo (24,291)
A61K 6 - Preparations for dentistry (18,259)
A61K 8 - Cosmetics or similar toilet preparations (170,551)
A61K 9 - Medicinal preparations characterised by special physical form (299,044)

Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449)
11/2004
11/18/2004	WO2004019893A3 Modulators of angiogenesis
11/18/2004	US20040230261 Method and assembly for treating pain of liquid nitrogen therapy
11/18/2004	US20040230257 Enhanced bioavailability of nutrients, pharmaceutical agents, and other bioactive substances through laser resonant homogenization or modification of molecular shape or crystalline form
11/18/2004	US20040230076 Raising pH of crude material aqueous suspension until solution clears; precipitating with acid addition
11/18/2004	US20040230043 Novel neurotrophic factors
11/18/2004	US20040229948 Administering phenyl butyrate compound or a salt, derivative or metabolite of phenyl butyrate in a pharmaceutically acceptable vehicle to prevent loss of brain and mental function associated with disorders of liver function
11/18/2004	US20040229923 Mixing a racemic mixture of enantiomers of pyrrolo[2,3-d]pyrimidine compounds in a solvent, with a resolving compound having a defined stereospecificity, to form a solution and with resolving agent being capable of binding with enantiomers to form a precipitate collecting precipitate and purifying
11/18/2004	US20040229912 Polymeric delivery formulations of leuprolide with improved efficacy
11/18/2004	US20040229895 Tetracyclic benzamide derivatives and methods of use thereof
11/18/2004	US20040229892 HIV integrase inhibitors
11/18/2004	US20040229855 Administering glucocorticoid receptor antagonist effective to ameliorate the symptoms of the postpartum psychosis, with the proviso that the first psychotic symptoms arise within nine months of childbirth, that the patient has never suffered any psychotic condition not triggered by childbirth
11/18/2004	US20040229816 Administering to the animal or human therapeutically effective amounts in unit dosage form comprising a carrier and at least one secretase inhibitor for therapy of tumors or proliferative disorders in an animal or human
11/18/2004	US20040229799 Saposin C-DOPS: a novel anti-tumor agent
11/18/2004	US20040229793 Compositions and methods for less immunogenic protein formulations
11/18/2004	US20040229790 Substance having an activity which modulates or inhibits proliferation of AILIM(activation inducible lymphocyte immunomodulatory molecule)-expressing cells or production of a cytokine; for treatment of rheumatoid arthritis, osteoarthritis
11/18/2004	US20040229781 Drug screening for agents to treat cardiovascular disorders; use of drug JTV-519, a member of the 1,4 benzothiazepine family of compounds, to repair leak in ryanodine receptor RyR2 channels
11/18/2004	US20040229773 Methods and compositions for increasing the anaerobic working capacity in tissues
11/18/2004	US20040229291 Screening and therapeutic methods relating to neurogenesis
11/18/2004	US20040228935 Plant extract comprising steroidal glycosides from the genus Trichocaulon or Hoodia produced by solvent extraction
11/18/2004	US20040228926 Administering Perna canaliculus and/or Mytilus edulis mussel component which exhibits cytotoxicity to malignant tumor cells
11/18/2004	US20040228924 Pharmaceutical products
11/18/2004	US20040228912 Once daily formulations of tetracyclines
11/18/2004	DE10297331T5 Behandlung und Diagnose von Insulin-resistenten Zuständen Treatment and diagnosis of insulin-resistant conditions
11/18/2004	CA2684022A1 Mesoderm and definitive endoderm cell populations
11/18/2004	CA2526875A1 Carbacephem beta-lactam antibiotics
11/18/2004	CA2524799A1 Stable immunoprophylactic and therapeutic compositions derived from transgenic plant cells and methods for production
11/18/2004	CA2524478A1 Lipid platinum complexes and methods of use thereof
11/18/2004	CA2524321A1 Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors
11/18/2004	CA2524293A1 Vectors and cells for preparing immunoprotective compositions derived from transgenic plants
11/18/2004	CA2524286A1 Nasal administration of the lh-rh analog leuprolide
11/18/2004	CA2524223A1 Morinda citrifolia-based formulation for inhibiting metastasis of carcinogenic cells
11/18/2004	CA2524217A1 Compositions for inducing immune responses
11/18/2004	CA2524172A1 Cngh0010 specific polynucleotides, polypeptides, antibodies, compositions, methods and uses
11/18/2004	CA2524026A1 Gemini vitamin d3 compounds and methods of use thereof
11/18/2004	CA2523870A1 Claudins' underexpression as markers of tumor metastasis
11/18/2004	CA2523620A1 Drug releasing biodegradable fiber for delivery of therapeutics
11/18/2004	CA2523242A1 Ginkgo biloba extract as a treatment for therapeutic induced neurotoxicity
11/18/2004	CA2523235A1 3-(1-naphthyl)-2-cyanopropanoic acid derivatives as estrogen receptor ligands
11/18/2004	CA2518506A1 Nitrosated and nitrosylated compounds, compositions and methods of use
11/18/2004	CA2504493A1 Method of preventing infections from bioterrorism agents with immunostimulatory cpg oligonucleotides
11/18/2004	CA2487058A1 Mesoderm and definitive endoderm cell populations
11/17/2004	EP1477497A1 Humanized immunoglobulins and their production and use
11/17/2004	EP1476580A2 Multiple virus replicon culture systems
11/17/2004	EP1476541A2 Novel cytokine zcytor17 ligand
11/17/2004	EP1476535A2 Stenoprophiluric generation and isolation of chemical products
11/17/2004	EP1476471A1 Nutraceuticals for the treatment, protection and restoration of connective tissues
11/17/2004	EP1476162A1 Controlled synthesis of ziprasidone and compositions thereof
11/17/2004	EP1476136A1 Pharmaceutical composition comprising n-((1-n-butyl-4-piperidinyl)menthyl)-3,4-dihydro-2h-(1,3)oxazino(3,2-a)indole-10-carboxamide or salt and process therefor comprising dry granulation
11/17/2004	EP1289999B1 Antitumoral analogs of et-743
11/17/2004	EP1272468B1 Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands
11/17/2004	EP1185274B1 Drug combinations comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4
11/17/2004	EP1137667B1 Analogues of glp-1
11/17/2004	EP1082321B1 Heterocyclic derivatives which inhibit factor xa
11/17/2004	CN1547476A Use of ATAZANAVIR in HIV therapy
11/17/2004	CN1547474A Skin-permeable selective cyclooxygenase-2 inhibitor composition
11/16/2004	US6818672 Treating endometriosis or infertility, or improving fertility
11/16/2004	US6818420 Methods of using FET labeled oligonucleotides that include a 3′-5′ exonuclease resistant quencher domain and compositions for practicing the same
11/16/2004	CA2159109C Therapeutic uses of keratinocyte growth factor
11/12/2004	WO2004100889A2 Cosmetic compositions and methods for using same to improve the aesthetic appearance of skin
11/11/2004	WO2004096366A1 9-azabicyclo’3.3.1!non-6-ee derivatives with a heteroatom at the 3-position as renin inhibitors
11/11/2004	WO2004096268A2 Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
11/11/2004	WO2004096235A2 Anti-cancer phosphonate analogs
11/11/2004	WO2004096161A2 Pharmaceutical compositions for treating painful neuropathy and methods of treating same
11/11/2004	WO2004096160A2 Vesicle-associated proteins
11/11/2004	WO2004096159A2 Saposin c-dops: a novel anti-tumor agent
11/11/2004	WO2004096157A2 Treatment of igai deposition diseases
11/11/2004	WO2004096156A2 Toll-like receptor 9 effector agents and uses thereof
11/11/2004	WO2004096155A2 Tablets and methods for modified release of hydrophilic and other active agents
11/11/2004	WO2004096154A2 Methods for treating degenerative diseases/injuries
11/11/2004	WO2004096153A2 Prostate cancer therapeutics and diagnostics based on conformers of prostatic acid phosphatase
11/11/2004	WO2004096152A2 In situ gelling self-reactive materials for embolization
11/11/2004	WO2004096151A2 Methods and devices for the sustained release of multiple drugs
11/11/2004	WO2004096149A2 Industrially scalable nucleoside synthesis
11/11/2004	WO2004096148A2 Tissue protective cytokine receptor complex, assays for identifying tissue protective compounds and uses thereof
11/11/2004	WO2004096147A2 Oxo-pyrimidine compounds
11/11/2004	WO2004096146A2 Method and composition for preventing, reducing and reversing ocular ischemic neuronal damage
11/11/2004	WO2004096145A2 Hemorrhoid treatment device
11/11/2004	WO2004096143A2 Methods for reducing or preventing transmission of nosocomial pathogens in a health care facility
11/11/2004	WO2004096142A2 Alk protein tyrosine kinase, cells and methods embodying and using same
11/11/2004	WO2004096141A2 Method for promoting uninterrupted sleep by administration of trospium chloride
11/11/2004	WO2004096140A2 Method and system for systemic delivery of growth arresting, lipid-derived bioactive compounds
11/11/2004	WO2004096139A2 Aza spiro alkane derivatives as inhibitors of metalloproteases
11/11/2004	WO2004096138A2 [18f]-furanosylpurine derivatives and uses thereof
11/11/2004	WO2004096136A2 Compositions comprising cationic microparticles and hcv e1e2 dna and methods of use thereof
11/11/2004	WO2004096135A2 Inhibitors of akt activity
11/11/2004	WO2004096134A2 Substituted 1,4-diazepines and uses thereof
11/11/2004	WO2004096131A2 Inhibitors of akt activity
11/11/2004	WO2004096130A2 Inhibitors of akt activity
11/11/2004	WO2004096129A2 Inhibitors of akt activity
11/11/2004	WO2004096128A2 Hiv integrase inhibitors
11/11/2004	WO2004096126A2 Treating hepatocellular carcinomas using therapeutic viruses
11/11/2004	WO2004096124A2 Compositions and methods for the diagnosis and treatment of tumor
11/11/2004	WO2004096123A2 Methods of promoting cell viability
11/11/2004	WO2004096121A2 Compositions and methods for preventing infection
11/11/2004	WO2004096120A2 Compounds that selectively bind to membranes of apoptotic cells
11/11/2004	WO2004096119A2 Topical pharmaceutical compositions, methods of manufacture thereof and articles of manufacture containing same
11/11/2004	WO2004096118A2 Composition for improving cognition and memory
11/11/2004	WO2004096116A2 Diazabicyclononene derivatives
11/11/2004	WO2004087053A9 Dipeptidyl peptidase inhibitors
11/11/2004	WO2004084831A3 Optimized expression of hpv 31 l1 in yeast

1 ... 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 ... 295